CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Ulrich Reininghaus

OPENALEX: A5039184361↗ORCID: 0000-0002-9227-5436↗

Affiliations

Organizations

Central Institute of Mental Healthauthorship · DE Heidelberg Universityauthorship · DE King's College Londonauthorship · GB Maastricht Universityauthorship · NL Maastricht University Medical Centreauthorship · NL University Hospital Heidelbergauthorship · DE

Public evidence

2 connected articles

Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.2021 · PubMed Central Open Access The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.2021 · PubMed Central Open Access

Matched by exact identifiers only. Profile data: Corpus/OpenAlex.

Ulrich Reininghaus - Medical Cannabis Research Engine